RHHBY
Roche Holdings AG ADR

3,570
Mkt Cap
$247.99B
Volume
2.01M
52W High
$46.00
52W Low
$34.10
PE Ratio
26.23
RHHBY Fundamentals
Price
$40.26
Prev Close
$45.52
Open
$45.26
50D MA
$42.81
Beta
0.34
Avg. Volume
1.77M
EPS (Annual)
$1.47
P/B
7.95
Rev/Employee
$665,306.28
Loading...
Loading...
News
all
press releases
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Zacks·8d ago
News Placeholder
More News
News Placeholder
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Zacks·10d ago
News Placeholder
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues. Stock falls.
Zacks·10d ago
News Placeholder
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
Zacks·11d ago
News Placeholder
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
Zacks·11d ago
News Placeholder
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
Zacks·15d ago
News Placeholder
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Zacks·15d ago
News Placeholder
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Zacks·16d ago
News Placeholder
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Zacks·18d ago
News Placeholder
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Zacks·18d ago

Latest RHHBY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.